申请人:Takeda Pharmaceutical Company Limited
公开号:EP1752457A1
公开(公告)日:2007-02-14
The present invention relates to a compound represented by the formula:
wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is -NR3-Y1-, -O-, -S-, -SO-, -SO2 or -CHR3- wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an optionally substituted ring structure, R1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R1 and R2, or R2 and R3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.
本发明涉及一种由式表示的化合物:
其中W是C(R1)或N,每个A是任选取代的芳基或杂芳基,X1是-NR3-Y1-、-O-、-S-、-SO-、-SO2或-CHR3-,其中R3是氢原子或任选取代的脂肪族烃基,或R3任选与A键合以形成任选取代的环结构,R1是氢原子或通过碳原子、氮原子或氧原子键合的任选取代的基团,R2是氢原子或通过碳原子或硫原子键合的任选取代的基团,或R1和R2键合以形成任选取代的环结构、R2 是氢原子或通过碳原子或硫原子键合的任选取代基团,或 R1 和 R2,或 R2 和 R3 任选键合以形成任选取代的环结构,或其盐,以及含有该化合物或其原药的酪氨酸激酶抑制剂或预防或治疗癌症的制剂。